News
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
BerGenBio Reports Second Quarter 2023 Financial Results
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast
BerGenBio ASA: Share capital increase registered
BerGenBio ASA - Information about the Warrants issued in connection with the Rights Issue
BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update
BerGenBio ASA – Correction of final results of the Rights Issue
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO